ANAB
ANAPTYSBIO, INC
$56.07
+3.37%
$1.6B
No data for this timeframe.
Vol
Market Cap$1.6B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders50 funds
Inst. Value$616.5M
Inst. Activity10 buys / 9 sells
Insider Activity0B / 3S
Insider Net $-$1.3M
Reddit Sentiment50° Neutral
SEC Reports14
Press Releases3
Recent Activity
Dec 12, 2026
fda_pdufa
PDUFA: ANAB — imsidolimab in generalized pustular psoriasis (GPP) — 2026-12-12
FDA target action date 2026-12-12 for ANAB (ANAPTYSBIO, INC). Drug: imsidolimab. Indication: general
Jun 11, 2026
SEC
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 notice of intent to sell 35,000 common shares valued at approx
144 — Impact 6/10
Jun 10, 2026
SEC
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 10, 2026, indicating intent to sell 20,000 shares (~$1
144 — Impact 5/10
Jun 8, 2026
SEC
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 notice of intent to sell 21,987 shares of common stock, with a
144 — Impact 5/10
May 11, 2026
Insider
Hughes Owen was granted 11,250 shares
Director
May 11, 2026
Insider
Murphy Christopher M. was granted 25,765 shares
Chief Financial Officer
Apr 20, 2026
Insider
Faga Daniel disposed of 11,000 shares
President, CEO
Inst.
BANK OF AMERICA CORP — DOUBLED
501,086 shares ($27.8M)
Price Targets
$87.09
+55.3% upside
Strong Buy
Current $56.07
Low $70.00
Median $81.00
High $140.00
11 analysts
$70.00
$140.00
Analyst Ratings
6Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | UBS | MAINTAIN | Buy → Buy |
| May 13, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| May 4, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Apr 28, 2026 | Leerink Partners | MAINTAIN | Outperform → Outperform |
| Apr 22, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.14 ▼ -49.9% | $-0.85 — $1.03 | 111% YoY | 5 |
| Next Q | $0.38 ▼ -21.3% | $-0.08 — $1.29 | -26% YoY | 6 |
| Current FY | $-0.23 ▼ -125.9% | $-2.63 — $2.49 | 50% YoY | 5 |
| Next FY | $5.24 ▲ +7.2% | $2.86 — $8.77 | 2369% YoY | 5 |
Latest Reports
BEARISH
144
6/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 notice of intent to sell 35,000 common shares valued at approx
Jun 11, 2026
BEARISH
144
5/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 10, 2026, indicating intent to sell 20,000 shares (~$1
Jun 10, 2026
BULLISH
Press
7/10
AnaptysBio announced a favorable court ruling in its ongoing litigation with Tesaro/GSK, with the Delaware Chancery Cour
Apr 24, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $93.2M | — |
| MORGAN STANLEY | $55.1M | TRIM |
| STATE STREET CORP | $55.0M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $47.3M | — |
| D. E. Shaw & | $32.1M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 11, 2026 | Hughes Owen | A | $0.00 |
| May 11, 2026 | Murphy Christopher | A | $0.00 |
| Apr 20, 2026 | Faga Daniel | D | $0.00 |
| Apr 20, 2026 | Faga Daniel | D | $0.00 |
| Apr 20, 2026 | Faga Daniel | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $616.5M total value (11,116,618 shares) as of 2026-Q1. Top holders: BlackRock,, MORGAN, STATE. Net buying activity: 10 institutions added/increased vs 9 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 1,681,380 | $93.2M | 15.1% | — |
| 2 | MORGAN STANLEY | 993,905 | $55.1M | 8.9% | TRIM -33.5% |
| 3 | STATE STREET CORP | 992,445 | $55.0M | 8.9% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 853,151 | $47.3M | 7.7% | — |
| 5 | D. E. Shaw & Co., Inc. | 579,296 | $32.1M | 5.2% | ADD +91.9% |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 519,870 | $28.8M | 4.7% | — |
| 7 | BANK OF AMERICA CORP /DE/ | 501,086 | $27.8M | 4.5% | DOUBLED +283.2% |
| 8 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 492,120 | $27.3M | 4.4% | ADD +51.1% |
| 9 | FMR LLC | 472,704 | $26.2M | 4.3% | DOUBLED +1643.8% |
| 10 | TWO SIGMA INVESTMENTS, LP | 465,083 | $25.8M | 4.2% | — |
| 11 | FEDERATED HERMES, INC. | 364,121 | $20.2M | 3.3% | ADD +54.9% |
| 12 | Woodline Partners LP | 344,256 | $19.1M | 3.1% | TRIM -31.3% |
| 13 | GOLDMAN SACHS GROUP INC | 332,743 | $18.5M | 3.0% | — |
| 14 | Nuveen, LLC | 316,065 | $17.5M | 2.8% | — |
| 15 | CITADEL ADVISORS LLC | 233,450 | $12.9M | 2.1% | — |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 192,687 | $10.7M | 1.7% | ADD +31.4% |
| 17 | Connor, Clark & Lunn Investment Management Ltd. | 158,562 | $8.8M | 1.4% | ADD +29.5% |
| 18 | VANGUARD FIDUCIARY TRUST CO | 135,082 | $7.5M | 1.2% | — |
| 19 | HSBC HOLDINGS PLC | 125,717 | $7.1M | 1.2% | — |
| 20 | Invesco Ltd. | 121,103 | $6.7M | 1.1% | DOUBLED +192.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | 130,767 | 501,086 | +283.2% | $27.8M | 2026-Q1 |
| FMR LLC | DOUBLED | 27,108 | 472,704 | +1643.8% | $26.2M | 2026-Q1 |
| Woodline Partners LP | TRIM | 501,023 | 344,256 | -31.3% | $19.1M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | ADD | 122,476 | 158,562 | +29.5% | $8.8M | 2026-Q1 |
| Trexquant Investment LP | ADD | 58,809 | 85,167 | +44.8% | $4.7M | 2026-Q1 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | TRIM | 229,137 | 78,952 | -65.5% | $4.4M | 2026-Q1 |
| Point72 Asset Management, L.P. | NEAR_EXIT | 1,932,890 | 55,303 | -97.1% | $3.1M | 2026-Q1 |
| DEUTSCHE BANK AG\ | DOUBLED | 14,381 | 52,038 | +261.9% | $2.9M | 2026-Q1 |
| MACKENZIE FINANCIAL CORP | ADD | 24,228 | 33,720 | +39.2% | $1.9M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | DOUBLED | 8,955 | 27,619 | +208.4% | $1.5M | 2026-Q1 |
| CREDIT AGRICOLE S A | TRIM | 40,000 | 20,000 | -50.0% | $1.1M | 2026-Q1 |
| Russell Investments Group, Ltd. | TRIM | 19,714 | 13,288 | -32.6% | $737.0K | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | ADD | 5,682 | 10,166 | +78.9% | $563.8K | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 4,966 | 7,654 | +54.1% | $424.5K | 2026-Q1 |
| ExodusPoint Capital Management, LP | NEAR_EXIT | 83,313 | 7,260 | -91.3% | $402.6K | 2026-Q1 |
| TUDOR INVESTMENT CORP ET AL | TRIM | 17,305 | 4,962 | -71.3% | $275.2K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | TRIM | 963 | 649 | -32.6% | $36.0K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 65 | 326 | +401.5% | $18.1K | 2026-Q1 |
| HRT FINANCIAL LP | TRIM | 70,130 | 40,504 | -42.2% | $2.2K | 2026-Q1 |
| MORGAN STANLEY | TRIM | 1,556,258 | 1,034,562 | -33.5% | $50.2M | 2025-Q4 |
| D. E. Shaw & Co., Inc. | ADD | 349,360 | 670,288 | +91.9% | $32.5M | 2025-Q4 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | 370,458 | 559,744 | +51.1% | $27.1M | 2025-Q4 |
| FEDERATED HERMES, INC. | ADD | 193,327 | 299,416 | +54.9% | $14.5M | 2025-Q4 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | DOUBLED | 9,321 | 229,137 | +2358.3% | $11.1M | 2025-Q4 |
| Invesco Ltd. | DOUBLED | 42,381 | 124,006 | +192.6% | $6.0M | 2025-Q4 |
7 unique insiders with 16 transactions. Net insider value: -$1.3M ($0.00 bought, $1.3M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 11, 2026 | Hughes Owen | Director | AWARD | 11,250 | — | — |
| May 11, 2026 | Murphy Christopher M. | Chief Financial Officer | AWARD | 25,765 | — | — |
| Apr 20, 2026 | Faga Daniel | President, CEO | D | 11,000 | — | — |
| Apr 20, 2026 | Faga Daniel | President, CEO | D | 11,000 | — | — |
| Apr 20, 2026 | Faga Daniel | President, CEO | AWARD | 11,000 | — | — |
| Apr 20, 2026 | RENTON HOLLINGS | Director | D | 15,000 | — | — |
| Apr 20, 2026 | RENTON HOLLINGS | Director | AWARD | 15,000 | — | — |
| Apr 20, 2026 | Schmid John P. | Director | D | 15,000 | — | — |
| Apr 20, 2026 | Schmid John P. | Director | AWARD | 15,000 | — | — |
| Apr 20, 2026 | Orwin John A | Director | D | 3,311 | — | — |
| Apr 20, 2026 | Orwin John A | Director | AWARD | 3,311 | — | — |
| Mar 30, 2026 | Schmid John P. | Director | SELL | 12,596 | $55.71 | $701.7K |
| Mar 27, 2026 | Faga Daniel | President, CEO | SELL | 510 | $56.61 | $28.9K |
| Mar 25, 2026 | Faga Daniel | President, CEO | AWARD | 34,300 | — | — |
| Feb 11, 2026 | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | SELL | 10,000 | $54.00 | $540.0K |
| Feb 11, 2026 | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | EXERCISE | 10,000 | $29.70 | $297.0K |
14 SEC filing reports analyzed. Sentiment: 1 bullish, 10 bearish, 0 mixed, 3 neutral. Avg impact: 4.9/10.
BEARISH
144
6/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 notice of intent to sell 35,000 common sha
Jun 11, 2026
BEARISH
144
5/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 10, 2026, indicating intent to sel
Jun 10, 2026
BEARISH
144
5/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 notice of intent to sell 21,987 shares of
Jun 8, 2026
BEARISH
144
5/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 5, 2026, indicating intent to sell
Jun 5, 2026
BEARISH
144
5/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 5, 2026, indicating intent to sell
Jun 5, 2026
BEARISH
144
5/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 notice of intent to sell 10,000 shares of
Jun 5, 2026
BEARISH
144
5/10
CEO Dennis Mulroy filed a Form 144 to sell 20,000 shares (~$1.0M at filing) via a stock option exerc
Jun 3, 2026
BEARISH
144
5/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 1, 2026, indicating intent to sell
Jun 1, 2026
NEUTRAL
8-K
2/10
AnaptysBio filed an 8-K under Item 7.01 to disclose that it has filed Form 8937 with the IRS regardi
May 29, 2026
NEUTRAL
144
3/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on May 28, 2026, indicating intent to sell
May 28, 2026
BEARISH
144
6/10
CEO Dennis Mulroy filed a Form 144 notice to sell 10,000 shares of AnaptysBio common stock, valued a
May 27, 2026
NEUTRAL
144
3/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on May 15, 2026, indicating intent to sell
May 15, 2026
BULLISH
PRESS-RELEASE
7/10
AnaptysBio reported Q4 2025 EPS of $1.58, a 268% beat vs consensus of -$0.94, indicating strong oper
May 4, 2026
BEARISH
CLUSTER
7/10
Two corporate insiders at AnaptysBio sold shares worth $731K within a 7-day window, including CEO Da
Apr 2, 2026
BULLISH
7/10
AnaptysBio announced a favorable court ruling in its ongoing litigation with Tesaro/GSK, with the De
Apr 24, 2026
MIXED
7/10
AnaptysBio is spinning off its biopharma operations into First Tracks Biotherapeutics, which secured
Mar 27, 2026
BULLISH
8/10
AnaptysBio reported strong Q4 and full-year 2025 financial results driven by a surge in Jemperli roy
Mar 3, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 17 analysts: 6 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$87.09 mean target
+55.3% upside
Strong Buy (1.27)
$70.00 Low
$140.00 High
| Metric | Value |
|---|---|
| Current Price | $56.07 |
| Target Low | $70.00 |
| Target Mean | $87.09 |
| Target Median | $81.00 |
| Target High | $140.00 |
| # Analysts | 11 |
| Recommendation | Strong Buy (1.27) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.14 | $-0.85 | $1.03 | 110.6% | -49.9% | 0↑ 3↓ | $0.0B | -9.6% | 5 |
| Next Q 2026-09-30 |
$0.38 | $-0.08 | $1.29 | -26.1% | -21.3% | 0↑ 3↓ | $0.0B | -65.5% | 6 |
| Current FY 2026-12-31 |
$-0.23 | $-2.63 | $2.49 | 49.8% | -125.9% | 0↑ 3↓ | $0.1B | -53.1% | 5 |
| Next FY 2027-12-31 |
$5.24 | $2.86 | $8.77 | 2369.2% | +7.2% | 1↑ 2↓ | $0.2B | 39.7% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.141 | |
| 7d ago | $0.389 | -0.248 |
| 30d ago | $0.283 | -0.141 |
| 60d ago | $-0.940 | +1.081 |
| 90d ago | $-0.879 | +1.020 |
8 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | UBS | MAINTAIN | Buy | Buy |
| May 13, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| May 4, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Apr 28, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Apr 22, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 21, 2026 | UBS | MAINTAIN | Buy | Buy |
| Mar 31, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Mar 30, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 17, 2026 | UBS | MAINTAIN | Buy | Buy |
| Mar 12, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 9, 2026 | Truist Securities | MAINTAIN | Hold | Hold |
| Mar 5, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Mar 4, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 20, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Dec 17, 2025 | Barclays | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 6 | 10 | 2 | 0 | 0 | 89% | |
| Apr 1, 2026 | 7 | 10 | 2 | 0 | 0 | 89% | |
| Mar 1, 2026 | 7 | 10 | 2 | 0 | 0 | 89% | |
| Feb 1, 2026 | 7 | 10 | 2 | 0 | 0 | 89% | |
| Jan 1, 2026 | 7 | 9 | 3 | 0 | 0 | 84% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 25, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Dec 12, 2026
fda_pdufa
PDUFA: ANAB — imsidolimab in generalized pustular psoriasis (GPP) — 2026-12-12
FDA target action date 2026-12-12 for ANAB (ANAPTYSBIO, INC). Drug: imsidolimab. Indication: generalized pustular psoriasis (GPP). FDA accepted the BL
May 12, 2026
earnings
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
<p>SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for <em>J
May 11, 2026
other
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
<p align="left">SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborati
May 7, 2026
earnings_calendar
ANAB Q1 2026 Earnings After Market Close — 2026-05-07
May 7, 2026
short_volume
Short Volume: ANAB — 55.5% short (0.3M / 0.5M)
Short: 286,023 | Exempt: 0 | TRF Vol: 515,581 | Short Ratio: 55.5% | Off-exchange volume (dark pool + OTC)
May 4, 2026
earnings
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
<p align="left">SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborati
May 4, 2026
earnings_calendar
ANAB Q1 2026 Earnings After Market Close — 2026-05-04
Apr 24, 2026
contract
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
<p align="left">SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collabora
Apr 20, 2026
other
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
<p>SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of it
Apr 1, 2026
short_interest
FTD: ANAB — 21,487 shares ($1.2M) failed to deliver
Settlement: 20260401, Price: $55.46, FTD Value: $1,191,669.02, ANAPTYSBIO INC COM STK (DE)
Mar 27, 2026
other
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
<p>SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has approved the previo
Mar 27, 2026
offering
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
<p>SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its planned spin-off, First Tracks Biotherapeu
Mar 27, 2026
buyback
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
<p align="left">SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has author
Mar 9, 2026
earnings_calendar
ANAB Q4 2025 Earnings After Market Close — 2026-03-09
Mar 3, 2026
earnings
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
<p>SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innov